<SEC-DOCUMENT>0001213900-25-064283.txt : 20250715
<SEC-HEADER>0001213900-25-064283.hdr.sgml : 20250715
<ACCEPTANCE-DATETIME>20250715163019
ACCESSION NUMBER:		0001213900-25-064283
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250715
DATE AS OF CHANGE:		20250715

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-84759
		FILM NUMBER:		251125129

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Jiang Eugene
		CENTRAL INDEX KEY:			0001892728
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	MAIL ADDRESS:	
		STREET 1:		1197 LA PLURISSIMA PL
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94539
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Jiang Eugene -->
          <cik>0001892728</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <dateOfEvent>07/10/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001173313</issuerCIK>
        <issuerCUSIP>00091F304</issuerCUSIP>
        <issuerName>ABVC BIOPHARMA, INC.</issuerName>
        <address>
          <com:street1>44370 Old Warm Springs Blvd.</com:street1>
          <com:city>Fremont</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94538</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Eugene Jiang</personName>
          <personPhoneNum>(510) 668-0881</personPhoneNum>
          <personAddress>
            <com:street1>Chairman &amp; Chief Business Officer</com:street1>
            <com:street2>44370 Old Warm Springs Blvd.</com:street2>
            <com:city>Fremont</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94538</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001892728</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Eugene Jiang</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>3102265.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>3102265.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>131159.00</aggregateAmountOwned>
        <isAggregateExcludeShares>Y</isAggregateExcludeShares>
        <percentOfClass>18.50</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>(1) The Reporting Person holds 131,159 shares directly; his remaining voting power is a result of certain voting agreements that provide him with sole voting power over an aggregate of 2,141,407 shares held by others, as more fully described herein and sole voting power over 829,699 shares held by YuanGene Corporation.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.001 per share</securityTitle>
        <issuerName>ABVC BIOPHARMA, INC.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>44370 Old Warm Springs Blvd.</com:street1>
          <com:city>Fremont</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94538</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>Eugene Jiang</filingPersonName>
        <principalBusinessAddress>44370 Old Warm Springs Blvd., Fremont, CA 94538</principalBusinessAddress>
        <principalJob>Chairman of the Board of Directors and Chief Business Officer of the Issuer</principalJob>
        <hasBeenConvicted>N/A</hasBeenConvicted>
        <convictionDescription>N/A</convictionDescription>
        <citizenship>United States</citizenship>
      </item2>
      <item3>
        <fundsSource>The Reporting Person has acquired the subject securities in various ways since his original acquisition including but not limited to original issuances from the Issuer and equity compensation under the Issuers Equity Incentive Plan that the Reporting Person received as compensation for employment and Board membership. The Reporting Person also has voting rights to securities that the Reporting Person did not pay for. The Reporting Person holds 131,159 shares directly.

He was also appointed as the person with sole voting power over the shares held by YuanGene Corporation, who owns 829,699 shares of the Issuer's Common Stock.

As part of the investments made into the Company between June 20, 2025 and July 1, 2025, which resulted in the issuance of an aggregate of 153,850 shares (the "Summer Shares"), the investors entered into a Voting Rights Proxy Agreement, pursuant to which he/she agreed to transfer all of his/her voting rights over his/her share of the Summer Shares to the Reporting Person for the maximum time permitted by law.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Certain of the Issuer's shareholders sought to grant the Reporting Person voting rights with respect to such shareholder's shares.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The Reporting Person has voting control over 3,102,265shares of Common Stock of the Issuer, which represents 18.50% of the outstanding and issued Common Stock, based on 16,773,261 shares of the Issuer's Common Stock issued and outstanding as of June 27, 2025.</percentageOfClassSecurities>
        <numberOfShares>Please refer to rows 7-12 on the cover page.</numberOfShares>
        <transactionDesc>Between June 20, 2025 and July 1, 2025, the Issuer sold an aggregate of 153,850shares (the "Shares") of its Common Stock to Non-U.S. Persons (as defined in Regulation S under the Securities Act) (the "Investors"), pursuant to Regulation S thereunder ("Regulation S"). The Company received aggregate gross proceeds of $200,000. Each of the Investors entered into a Voting Rights Proxy Agreement, pursuant to which he/she agreed to transfer all of his/her voting rights to the Reporting Person for the maximum time permitted by law.</transactionDesc>
        <listOfShareholders>The Investors have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.</listOfShareholders>
        <date5PercentOwnership>N/A</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Other than as described in this Schedule, to the knowledge of the Reporting Person, there are no contracts, arrangements, understandings, or relationships (legal or otherwise) between the Reporting Person and any other persons with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>(1) Form of Voting Rights Proxy Agreement (incorporated by reference to the Current Report on Form 8-K filed on April 30, 2025).</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Eugene Jiang</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Eugene Jiang</signature>
          <title>Eugene Jiang, Chairman &amp; Chief Business Officer</title>
          <date>07/15/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
